Human pathogenic streptococcal proteomics and vaccine development.
about
The pathogenicity of the Streptococcus genusZebrafish and Streptococcal InfectionsComparative proteomic analysis of extracellular proteins of Clostridium perfringens type A and type C strains.Region specific and worldwide distribution of collagen-binding M proteins with PARF motifs among human pathogenic streptococcal isolates.Disease manifestations and pathogenic mechanisms of Group A Streptococcus.The Streptococcus pyogenes proteome: maps, virulence factors and vaccine candidates.Impact of immunization against SpyCEP during invasive disease with two streptococcal species: Streptococcus pyogenes and Streptococcus equiThe fibrinogen-binding M1 protein reduces pharyngeal cell adherence and colonization phenotypes of M1T1 group A Streptococcus.Vaccination against rheumatic heart disease: a review of current research strategies and challenges.Vaccination with Streptococcus pyogenes nuclease A stimulates a high antibody response but no protective immunity in a mouse model of infection.Rheumatic fever pathogenesis: Approach in research needs change.Group A streptococcal cysteine protease cleaves epithelial junctions and contributes to bacterial translocation.Variability in the distribution of genes encoding virulence factors and putative extracellular proteins of Streptococcus pyogenes in India, a region with high streptococcal disease burden, and implication for development of a regional multisubunit vProteome analysis of the hyaluronic acid-producing bacterium, Streptococcus zooepidemicus.Towards developing a vaccine for rheumatic heart disease.Conserved anchorless surface proteins as group A streptococcal vaccine candidates.
P2860
Q24600416-564364EC-26D0-46BE-9A86-08BA9333D091Q28085714-FB31EDA2-C415-4434-9084-4BEE9B835A03Q34119364-21B777D6-A21E-4BA9-81C7-211E8AD69B03Q34131103-9D695208-948C-4DC4-9FEF-245B49D5E569Q34413457-6FA0F802-DB64-4152-B5F3-1F5AB9D098DDQ34974840-2AFE8D7A-C127-4FC8-8C60-DE608CB695D5Q37380367-D1BEC11A-EEF3-44C2-A821-747C67641B1EQ37563501-9B821C69-1251-43EA-BBB1-BDF95A34E4BEQ38021366-78C44800-BAAC-4FBE-90C7-6246D089D37DQ40196934-74C12916-5C79-43A3-8830-249B27FB3466Q40269065-E6ABE4D3-4C9E-445C-A4F9-9BD995FB9470Q40600045-9DCEEDDC-F00A-4396-AC97-A77AE5CC568FQ41426800-52E259B0-9F57-45F8-BDD8-E86EF51C2FFAQ41853128-85C6B433-D67A-4FFB-BB16-3D93B02DB25FQ41928281-E3E93CF0-71AB-46F8-8F91-4EC96C2B9ACAQ43405072-6018F15F-37FE-4335-9C9E-1BD679A572FD
P2860
Human pathogenic streptococcal proteomics and vaccine development.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Human pathogenic streptococcal proteomics and vaccine development.
@en
Human pathogenic streptococcal proteomics and vaccine development.
@nl
type
label
Human pathogenic streptococcal proteomics and vaccine development.
@en
Human pathogenic streptococcal proteomics and vaccine development.
@nl
prefLabel
Human pathogenic streptococcal proteomics and vaccine development.
@en
Human pathogenic streptococcal proteomics and vaccine development.
@nl
P2860
P50
P356
P1476
Human pathogenic streptococcal proteomics and vaccine development.
@en
P2093
Jason N Cole
Vidiya Ramachandran
P2860
P304
P356
10.1002/PRCA.200780048
P577
2008-03-01T00:00:00Z